5 results
To evaluate the inter- and intra-subject variability in pharmacokinetics (PK) and pharmacodynamics (PD) of study drug following a two-period repeated single dose of 2 mg delivered by subcutaneous (SC) injection in healthy volunteers.
The primary objective of this study is to assess the efficacy of pridopidine 67.5 to 112.5 mg twice daily (bid) on motor impairment in patients with HD after 26 weeks of treatment using the Unified Huntington*s Disease Rating Scale (UHDRS) Total…
To study the incidence of 'sustained' ventricular tachyarrhythmias in patients with HFpEF.
Primary Objective: The primary objective of this study is to evaluate safety and tolerability of pridopidine in patients with HD.Secondary Objectives: The secondary objectives of the study are to assess the effects of long-term, open-label dosing…
2.2 Primary ObjectiveTo study clinical factors, (blood) biomarkers and genetic markers related to AF progression in patients diagnosed with recent onset self-terminating AF with special reference to hypercoagulability.2.3 Secondary Objectives1. To…